Pharmacotherapy for weight loss in adults with type 2 diabetes mellitus
Cochrane Database of Systematic ReviewsPublished 17 January 2005Open access
Susan L. Norris, Xuanping Zhang, Alison Avenell, Edward W. Gregg, Christopher H. Schmid, Joseph Lau
Citations113
SJR quartileQ1
SJR score1.62
SNIP2.04
Generate an AI Snapshot to get a quick, structured summary of this paper.
Study Snapshot
ObjectiveStudy objective
MethodsResearch methodology
PopulationPopulation studied
Sample sizeSample sizes
OutcomesStudy outcomes here
ResultsStudy results comes here
LimitationsResearch study limitations comes here
A concise AI-generated summary of the paper will appear here once you click Generate AI Snapshot.
TL;DR
Fluoxetine, orlistat, and sibutramine can achieve statistically significant weight loss over 12 to 57 weeks, but the magnitude of weight loss is modest, however, and the long-term health benefits remain unclear.
Abstract
Fluoxetine, orlistat, and sibutramine can achieve statistically significant weight loss over 12 to 57 weeks. The magnitude of weight loss is modest, however, and the long-term health benefits remain unclear. The safety of sibutramine is uncertain. There is a paucity of data on other drugs for weight loss or control in persons with type 2 diabetes.
Keywords
Medicine
Controlled Clinical TrialsMeta-analysis in clinical trials
39,316 Citations1986Rebecca DerSimonian, Nan M. Laird
This paper examines eight published reviews each reporting results from several related trials in order to evaluate the efficacy of a certain treatment for a specified medical condition and suggests a simple noniterative procedure for characterizing the distribution of treatment effects in a series of studies.
New England Journal of MedicineThe Effect of Intensive Treatment of Diabetes on the Development and Progression of Long-Term Complications in Insulin-Dependent Diabetes Mellitus
24,537 Citations1993David M. Nathan
Intensive therapy effectively delays the onset and slows the progression of diabetic retinopathy, nephropathy, and neuropathy in patients with IDDM.
The LancetIntensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33)
20,069 Citations1998
The effects of intensive blood-glucose control with either sulphonylurea or insulin and conventional treatment on the risk of microvascular and macrovascular complications in patients with type 2 diabetes in a randomised controlled trial were compared.
New England Journal of MedicineReduction in the Incidence of Type 2 Diabetes with Lifestyle Intervention or Metformin
19,026 Citations2002Diabetes Prevention Program Research Group
Lifestyle changes and treatment with metformin both reduced the incidence of diabetes in persons at high risk and the lifestyle intervention was more effective than meetformin.
Diabetic MedicineDefinition, diagnosis and classification of diabetes mellitus and its complications. Part 1: diagnosis and classification of diabetes mellitus. Provisional report of a WHO Consultation
15,141 Citations1998K. G. M. M. Alberti, Paul Zimmet +1 more
A WHO Consultation has taken place in parallel with a report by an American Diabetes Association Expert Committee to re‐examine diagnostic criteria and classification of diabetes mellitus and is hoped that the new classification will allow better classification of individuals and lead to fewer therapeutic misjudgements.
New England Journal of MedicinePrevention of Type 2 Diabetes Mellitus by Changes in Lifestyle among Subjects with Impaired Glucose Tolerance
10,818 Citations2001Jaakko Tuomilehto, Jaana Lindström +17 more
Type 2 diabetes can be prevented by changes in the lifestyles of high-risk subjects by means of individualized counseling aimed at reducing weight, total intake of fat, and intake of saturated fat and increasing intake of fiber and physical activity.
Diabetes CareGlobal Burden of Diabetes, 1995–2025: Prevalence, numerical estimates, and projections
6,342 Citations1998Hilary King, Ronald E. Aubert +1 more
This report supports earlier predictions of the epidemic nature of diabetes in the world during the first quarter of the 21st century and provides a provisional picture of the characteristics of the diabetes epidemic.
JAMAPrevalence and Trends in Obesity Among US Adults, 1999-2000
6,205 Citations2002Katherine M. Flegal
The increases in the prevalences of obesity and overweight previously observed continued in 1999-2000, and increases occurred for both men and women in all age groups and for non-Hispanic whites, non- Hispanic blacks, and Mexican Americans.
BiometricsThe Combination of Estimates from Different Experiments
5,203 Citations1954William G. Cochran
DiabetesClassification and Diagnosis of Diabetes Mellitus and Other Categories of Glucose Intolerance
4,942 Citations1979National Diabetes Data Group
Hormone Research in PaediatricsDietary Advanced Glycation End Products and Their Potential Role in Cardiometabolic Disease in Children
4,018 Citations2016Anshu Gupta, Jaime Uribarri
Available evidence suggests an involvement of AGEs in the pathogenesis of adiposity and β-cell failure in children, and potential areas for further research to investigate underlying mechanisms are proposed.
JAMAThe Continuing Epidemics of Obesity and Diabetes in the United States
2,742 Citations2001Ali H. Mokdad
The prevalence of obesity and diabetes continues to increase among US adults, and interventions are needed to improve physical activity and diet in communities nationwide.
Food & Nutrition ResearchGlobal strategy on diet, physical activity and health
2,322 Citations2004Gösta Samuelson
An expert report aiming to design strategies in promoting healthy diets and physical activity behaviours was published a year ago by the United Nations Food and Agriculture Organization.
Annals of Internal MedicineMedical Hazards of Obesity
1,384 Citations1993F. Xavier Pi‐Sunyer
Obesity occurring early in life affects intervening risk factors such as diabetes and hypertension much more strongly than that occurring later in life, when these risk factors become more important variables.
Journal of Clinical EpidemiologyPublication bias in meta-analysis its causes and consequences
1,254 Citations2000Alison J. Thornton
The design of the meta-analysis itself, and the studies included in it, are shown to be important among a number of sources of publication bias.
BMJBy how much and how quickly does reduction in serum cholesterol concentration lower risk of ischaemic heart disease?
1,220 Citations1994M R Law, Nicholas Wald +1 more
The results from the cohort studies, international comparisons, and clinical trials are remarkably consistent and estimate that a long term reduction in serum cholesterol concentration of 0.6 mmol/l (10%), which can be achieved by moderate dietary change,owers the risk of ischaemic heart disease by 50%" at age 40, falling to 20% at age 70.
The LancetRandomised placebo-controlled trial of orlistat for weight loss and prevention of weight regain in obese patients
1,203 Citations1998Lars Sjöström, Aila Rissanen +5 more
Orlistat taken with an appropriate diet promotes clinically significant weight loss and reduces weight regain in obese patients over a 2-year period and the use of orlistat beyond 2 years needs careful monitoring with respect to efficacy and adverse events.
Diabetes CareDiabetes trends in the U.S.: 1990-1998.
1,044 Citations2000Ali H. Mokdad, Earl S. Ford +5 more
The prevalence of diabetes continues to increase rapidly in the U.S. and will become even more common because the prevalence of obesity is also rising, and major efforts are needed to alter these trends.
American Journal of Clinical NutritionCardiorespiratory fitness, body composition, and all-cause and cardiovascular disease mortality in men
1,031 Citations1999Chong Do Lee, Steven N. Blair +1 more
The health benefits of leanness are limited to fit men, and being fit may reduce the hazards of obesity.
New England Journal of MedicineAdverse Cardiovascular and Central Nervous System Events Associated with Dietary Supplements Containing Ephedra Alkaloids
959 Citations2000Christine Haller, N BENOWITZ
An independent review of reports of adverse events related to the use of supplements that contained ephedra alkaloids was conducted to assess causation and to estimate the level of risk the Use of these supplements poses to consumers.
JAMAWeight Control and Risk Factor Reduction in Obese Subjects Treated for 2 Years With Orlistat
937 Citations1999Michael Davidson, Jonathan Hauptman +9 more
Two-year treatment with orlistat plus diet significantly promotes weight loss, lessens weight regain, and improves some obesity-related disease risk factors.
The LancetEffect of sibutramine on weight maintenance after weight loss: a randomised trial
816 Citations2000W. P. T. James, Arne Astrup +6 more
Changes in concentrations of HDL cholesterol, VLDL cholesterol, and triglyceride, but not LDL cholesterol, exceed those expected either from weight loss alone or when induced by other selective therapies for low concentrations of LDL cholesterol relating to coronary heart disease.
Annals of Internal MedicineGuidelines for Meta-analyses Evaluating Diagnostic Tests
760 Citations1994Les Irwig, Anna N. A. Tosteson +5 more
These guidelines are used to review 11 journal articles published from January 1990 through December 1991 whose primary purpose was to assess the accuracy of a diagnostic test against a concurrent reference standard using meta-analysis, and the guidelines are based on current concepts of how to assess diagnostic tests and conduct meta-analyses.
JAMAAssociation of Funding and Conclusions in Randomized Drug Trials
744 Citations2003Bodil Als‐Nielsen, Wendong Chen +2 more
Conclusions in trials funded by for-profit organizations may be more positive due to biased interpretation of trial results, and readers should carefully evaluate whether conclusions in randomized trials are supported by data.
Diabetes CareRole of Orlistat in the Treatment of Obese Patients With Type 2 Diabetes: A 1-year randomized double-blind study
657 Citations1998Priscilla Hollander, Steven C. Elbein +13 more
Orlistat is an effective treatment modality in obese patients with type 2 diabetes with respect to clinically meaningful weight loss and maintenance of weight loss, improved glycemic control, and improved lipid profile.
Archives of Internal MedicineEffects of Weight Loss and Sodium Reduction Intervention on Blood Pressure and Hypertension Incidence in Overweight People With High-Normal Blood Pressure
637 Citations1997
Diabetes CareIntentional weight loss and mortality among overweight individuals with diabetes.
565 Citations2000David F. Williamson, Theodore J. Thompson +4 more
Intentional weight loss was associated with substantial reductions in mortality in this observational study of overweight individuals with diabetes.
The LancetDoes blinding of readers affect the results of meta-analyses?
483 Citations1997Jesse A. Berlin
Archives of Internal MedicineLong-term Effects of Modest Weight Loss in Type II Diabetic Patients
472 Citations1987Rena R. Wing
The improvement in glycemic control for a given weight loss was greater initially than at one year, suggesting that energy restriction, in addition to weight loss, may contribute to initial improvement.
Diabetes CareFluoxetine for depression in diabetes: a randomized double-blind placebo-controlled trial.
449 Citations2000Patrick J. Lustman, Kenneth E. Freedland +2 more
Fluoxetine effectively reduces the severity of depression in diabetic patients and after only 8 weeks, this treatment also produced a trend toward better glycemic control.
PubMedTreatment of obesity by very low calorie diet, behavior therapy, and their combination: a five-year perspective.
422 Citations1989Wadden Ta, Sternberg Ja +3 more
A significantly greater percentage of subjects in the behavior therapy alone and combined treatment conditions maintained their full end-of-treatment weight losses than in the very low calorie diet alone condition.
Journal of Clinical EpidemiologyMisleading funnel plot for detection of bias in meta-analysis
409 Citations2000Jinling Tang, Joseph LY Liu
It is demonstrated that the shape of a funnel plot is largely determined by the arbitrary choice of the method to construct the plot, and that the discrepancies between large trials and corresponding meta-analyses and heterogeneity in meta-Analyses may also be determined by how they are evaluated.
Obesity ResearchSibutramine Produces Dose‐Related Weight Loss
384 Citations1999George A. Bray, George L. Blackburn +9 more
Sibutramine administered once daily for 24 weeks in the weight loss phase of treatment for uncomplicated obesity produced dose-related weight loss and was well tolerated, including small mean increases in blood pressure and heart rate.
PubMedLong-term follow-up of behavioral treatment for obesity: patterns of weight regain among men and women.
381 Citations1989F. Matthew Kramer, Robert W. Jeffery +2 more
Although significant mean weight loss was evident at long-term follow-up, a negatively accelerating pattern of weight regain was the predominant outcome and consistent sex differences were found, with women having better weight loss maintenance than men.
Cochrane Database of Systematic ReviewsLong-term pharmacotherapy for obesity and overweight
379 Citations2003Raj Padwal, Diana Rucker +3 more
Average weight losses with current anti-obesity agents appear modest but may be of clinical benefit, and better studies designed to examine mortality and cardiovascular morbidity are required to fully evaluate any potential benefit of such agents.
Archives of Family MedicineOrlistat in the Long-term Treatment of Obesity in Primary Care Settings
370 Citations2000Jonathan Hauptman
This long-term study indicates that orlistat is an effective adjunct to dietary intervention in the treatment of obesity in primary care settings and was well tolerated, although treatment resulted in a higher incidence of gastrointestinal events.
Archives of Internal MedicineEffects of Weight Loss With Orlistat on Glucose Tolerance and Progression to Type 2 Diabetes in Obese Adults
358 Citations2000Steven B. Heymsfield, Karen R. Segal +6 more
The addition of orlistat to a conventional weight loss regimen significantly improved oral glucoseolerance and diminished the rate of progression to the development of impaired glucose tolerance and type 2 diabetes.
The American Journal of MedicineLong-term maintenance of weight loss after a very-low-calorie diet: a randomized blinded trial of the efficacy and tolerability of sibutramine
348 Citations1999M Apfelbaum, P Vague +4 more
Following a very-low-calorie diet, sibutramine is effective in maintaining and improving weight loss for up to 1 year.
Diabetes CareContinuous subcutaneous infusion of glucagon-like peptide 1 lowers plasma glucose and reduces appetite in type 2 diabetic patients.
335 Citations1999M. Toft-Nielsen, Sten Madsbad +1 more
It is concluded that 48-h continuous subcutaneous infusion of GLP-1 in type 2 diabetic patients lowers fasting as well as meal-related plasma glucose, reduces appetite, has no gastrointestinal side effects, and has no negative effect on blood pressure.
Obesity ResearchObesity and Disease Management: Effects of Weight Loss on Comorbid Conditions
333 Citations2001James W. Anderson, Elizabeth Konz
Obesity and/or weight gain are associated with major risk for CHD and weight loss significantly improves serum lipid parameters, blood pressure, and fasting blood glucose values.
International Journal of ObesityOne-year treatment of obesity: a randomized, double-blind, placebo-controlled, multicentre study of orlistat, a gastrointestinal lipase inhibitor
321 Citations2000Nick Finer, W. P. T. James +3 more
Orlistat was well tolerated and offered a promising new approach to the long-term management of obesity, and produced greater and more frequent significant weight loss than placebo during 1 y of treatment.
Archives of Internal MedicineEffects of weight loss and sodium reduction intervention on blood pressure and hypertension incidence in overweight people with high-normal blood pressure. The Trials of Hypertension Prevention, phase II. The Trials of Hypertension Prevention Collaborative Research Group
318 Citations1997
In overweight adults with high-normal BP, weight loss and reduction in sodium intake, individually and in combination, were effective in lowering systolic and diastolic BP, especially in the short-term (6 months); although the effects on average BP declined over time, reductions in hypertension incidence were achieved.
Medical Clinics of North AmericaBEHAVIORAL TREATMENT OF OBESITY
314 Citations2000Thomas A. Wadden, Gary D. Foster
Diabetes CareClinical Efficacy of Orlistat Therapy in Overweight and Obese Patients With Insulin-Treated Type 2 Diabetes
312 Citations2002David E. Kelley, George A. Bray +5 more
Orlistat therapy produces clinically significant weight loss, with improvements in glycemic control and cardiovascular disease risk factors, in overweight or obese patients with type 2 diabetes who have suboptimal metabolic control with insulin therapy.
PubMedBenefits of lifestyle modification in the pharmacologic treatment of obesity: a randomized trial.
305 Citations2001Thomas A. Wadden, Robert I. Berkowitz +3 more
The addition of group lifestyle modification to the pharmacologic management of obesity significantly improved weight loss and patients' satisfaction with treatment outcome.
Endocrine ReviewsCurrent and Potential Drugs for Treatment of Obesity
302 Citations1999George A. Bray, Frank L. Greenway
The objective of this study was to evaluate the effectiveness of antiobesity treatment against a broad range of drugs that alter metabolism, including thyroid hormone, adrenergic thermogenic drugs, and drugs that increase energy expenditure.
American Journal of Clinical NutritionOrlistat, a lipase inhibitor, for weight maintenance after conventional dieting: a 1-y study
290 Citations1999James O. Hill, Jonathan Hauptman +6 more
The use of orlistat during periods of attempted weight maintenance minimizes weight readjustment and facilitates long-term improvement in obesity-related disease risk factors.
Diabetes CareEffect of Orlistat in Overweight and Obese Patients With Type 2 Diabetes Treated With Metformin
285 Citations2002John M. Miles, Lawrence A. Leiter +7 more
Orlistat is a useful adjunctive treatment for producing weight loss and improving glycemic control, serum lipid levels, and blood pressure in obese patients with type 2 diabetes who are being treated with metformin.
JAMALong-term Weight Loss With Sibutramine
274 Citations2001Alfred Wirth, Jessica Krause
Sibutramine, administered for 48 weeks to a typically obese population, results in clinically relevant weight loss compared with placebo, andTherapeutic equivalence of the 2 active treatments could be shown.
JAMAPhysician Interpretations and Textbook Definitions of Blinding Terminology in Randomized Controlled Trials
258 Citations2001P.J. Devereaux
It is suggested that both physicians and textbooks vary greatly in their interpretations and definitions of single, double, and triple blinding.
Archives of Internal MedicineEfficacy and Safety of Sibutramine in Obese White and African American Patients With Hypertension
247 Citations2000F. Gilbert McMahon, Ken Fujioka +6 more
In obese patients with controlled hypertension, sibutramine was an effective and well-tolerated treatment for weight loss and maintenance and was associated with significant improvements in serum levels of triglycerides, HDL-C, glucose, and uric acid.
Diabetes Obesity and MetabolismWeight loss with sibutramine improves glycaemic control and other metabolic parameters in obese patients with type 2 diabetes mellitus
244 Citations2000Ken Fujioka, T. B. Seaton +5 more
The objective was to determine the efficacy and tolerability of sibutramine hydrochloride in obese patients whose type 2 diabetes was poorly controlled on diet alone or with an oral antidiabetic agent.
Diabetes CareBromocriptine: a novel approach to the treatment of type 2 diabetes.
239 Citations2000Hanno Pijl, Satoru Ohashi +9 more
Bromocriptine improves glycemic control and glucose tolerance in obese type 2 diabetic patients and is associated with enhanced maximally stimulated insulin-mediated glucose disposal.
PubMedThe effect and safety of an ephedrine/caffeine compound compared to ephedrine, caffeine and placebo in obese subjects on an energy restricted diet. A double blind trial.
227 Citations1992Arne Astrup, Leif Breum +3 more
It is concluded, that in analogy with animal studies, the ephedrine/caffeine combination is effective, while caffeine andEphedrine separately are ineffective for the treatment of human obesity.
Archives of Internal MedicineEffects of a Very-Low-Calorie Diet on Long-term Glycemic Control in Obese Type 2 Diabetic Subjects
227 Citations1991Rena R. Wing
Use of the VLCD produced greater decreases in fasting glucose at the end of the 20-week program and at 1-year follow-up and greater long-term reductions in HbA1.
PubMedOrlistat (Ro 18-0647), a lipase inhibitor, in the treatment of human obesity: a multiple dose study.
209 Citations1995Marjolein Drent, Ingrid Larsson +7 more
Orlistat, in an apparently dose-dependent manner, leads to additional weight loss compared to diet alone and overall, is well tolerated.
Journal of Internal MedicineThe effect of orlistat on body weight and coronary heart disease risk profile in obese patients: The Swedish Multimorbidity Study
205 Citations2000Folke Lindgärde
The effect of orlistat on body weight and coronary heart disease risk profile in obese patients in the Swedish Multimorbidity Study is illustrated.
Behavior TherapyImproving long-term weight loss: Pushing the limits of treatment
198 Citations1987Kelly D. Brownell, Robert W. Jeffery
American Journal of PsychiatryA double-blind, placebo-controlled trial of fluoxetine plus behavior modification in the treatment of obese binge-eaters and non-binge- eaters
193 Citations1990Marsha D. Marcus, Rena R. Wing +4 more
Patients treated with fluoxetine plus behavior modification lost significantly more weight than those treated with placebo plusbehavior modification, however, the drug did not appear to have a differential benefit for binge-eaters.
Diabetes CareStrategies for Improving Maintenance of Weight Loss: Toward a continuous care model of obesity management
193 Citations1993Michael G. Perri, Samuel F. Sears +1 more
It is suggested that, after treatment for obesity, multifaceted programs comprised of continued professional contact, skills training, social support, and exercise, can enhance the long-term maintenance of weight loss.
Obesity ResearchA Double‐Blind Randomized Placebo‐Controlled Trial of Sibutramine
189 Citations1996George A. Bray, Donna H. Ryan +4 more
There was a dose-dependent reduction in body weight, with doses of 10, 15, 20 and 30 mg being significantly greater than placebo and weight loss was still continuing in the highest three doses at the end of the study.
ScienceEating Disorders and Obesity
186 Citations2003Susan Reslewic
There was too little attention paid to the emotional and psychological factors behind obesity and the poor relationship Americans seem to have with food, and a tax or other restrictions to the food supply are not going to solve the obesity and eating-disorder problems.
American Journal of Clinical NutritionInitial studies in humans with the novel gastrointestinal lipase inhibitor Ro 18–0647 (tetrahydrolipstatin)
179 Citations1992JB Hauptman, FS Jeunet +1 more
Initial studies in humans have shown that Ro 18-0647 can reliably increase fecal fat excretion and further research must be conducted to determine whether clinical endpoints of weight loss or cholesterol lowering can be produced by using this new pharmacologic principle.
Diabetes Obesity and MetabolismSibutramine is effective for weight loss and diabetic control in obesity with type 2 diabetes: a randomised, double‐blind, placebo‐controlled study
170 Citations2000Nick Finer, S R Bloom +3 more
To assess the efficacy and tolerability of sibutramine 15 mg once daily as a weight reduction agent in overweight and obese patients with type 2 diabetes when given with a customised, reduced‐calorie diet, and to evaluate the influence of weight loss on diabetic control.
American Journal of PsychiatryChanges in Weight During a 1-Year Trial of Fluoxetine
169 Citations1999David Michelson, Jay D. Amsterdam +7 more
It is found that after remission of depressive symptoms, weight gain for patients taking fluoxetine for longer periods is not different from that for patientsTaking placebo and is most likely related to recovery from depression.
Archives of General PsychiatryBehavior Therapy and Pharmacotherapy for Obesity
169 Citations1981Linda W. Craighead
One-year follow-up of all living patients who completed treatment showed a striking reversal in the relative efficacy of the treatments, and adding pharmacotherapy to behavior therapy apparently compromised the long-term effects of the latter treatment.
Diabetes CareEffects of Moderate Weight Loss and Orlistat on Insulin Resistance, Regional Adiposity, and Fatty Acids in Type 2 Diabetes
168 Citations2004David E. Kelley, Lewis H. Kuller +4 more
At equivalent weight loss, conjunctive use of orlistat resulted in greater improvement in FFA levels and IS, and at comparable weight loss the effects of the intestinal lipase inhibitor or listat were examined at 6 months of treatment.
Diabetes CareA Randomized Trial of Sibutramine in the Management of Obese Type 2 Diabetic Patients Treated With Metformin
167 Citations2003Steven McNulty, Ehud Ur +1 more
Sibutramine can be an effective adjunct to metformin treatment in selected obese type 2 diabetic subjects and improves metabolic control in individuals who lose weight.
Diabetes Obesity and MetabolismEvaluation of the safety and efficacy of sibutramine, orlistat and metformin in the treatment of obesity
165 Citations2002A. Gokcel, Yüksel Gümürdülü +5 more
A randomized, prospective clinical trial is designed to study the efficacy and safety of 10“mg sibutramine twice daily, and compare this treatment with 120 mg orlistat three times daily (tid) and 850‰mg metformin (bid).
Obesity ResearchOriginal Articles Sibutramine Reduces Food Intake in Non‐Dieting Women with Obesity
159 Citations1998Barbara J. Rolls, David J. Shide +2 more
SIB reduced energy intake in women with obesity who were not attempting to lose weight in this double-blind, placebo-controlled, Latin square crossover study.
PubMedFluoxetine: a randomized clinical trial in the treatment of obesity.
157 Citations1994D. Goldstein, A H Rampey +4 more
Fluoxetine was well tolerated and appeared to be safe therapy for the treatment of obesity with efficacy demonstrated for 28 weeks, and two sites demonstrated greater efficacy than the study as a whole.
European Journal of Clinical PharmacologyEfficacy and tolerability of orlistat in the treatment of obesity: a 6-month dose-ranging study
153 Citations1998Luc F. Van Gaal, J. Broom +2 more
Orlistat treatment results in a dose-dependent reduction in body weight in obese subjects and is well tolerated and represents the optimal dosage regimen.
Diabetes Obesity and MetabolismThe effects of orlistat on body weight and glycaemic control in overweight patients with type 2 diabetes: a randomized, placebo‐controlled trial
148 Citations2002M Hanefeld, G. Sachse
The aim of this study is to assess the long‐term effects of orlistat on body weight, glycaemic control and cardiovascular risk factors in overweight patients with type 2 diabetes.
Diabetes CarePromoting Weight Loss in Type II Diabetes
141 Citations1996Sharon A. Brown, Sandra L. Upchurch +3 more
Dairy strategies are most effective for promoting short-term weight loss in type II diabetes, and effects of weight promotion strategies were smaller in experimental studies and for individuals over age 55.
American Journal of Preventive MedicineCan tailored interventions increase mammography use among HMO women?
119 Citations2000Isaac M. Lipkus, Barbara K. Rimer +2 more
Results suggest that telephone counseling, rather than tailored print, might be the preferred first-line intervention for getting nonadherent women on schedule for mammography screening.
American Journal of Clinical NutritionFluoxetine's effect on weight loss in obese subjects
116 Citations1991LL Darga, Leslie Carroll-Michals +2 more
By the end of the study, each group weighed significantly less than they did at baseline although the difference between groups was no longer significant (P greater than 0.05), and those on fluoxetine regained a mean of 4.2 kg from their lowest weight whereas the placebo group did not.
PubMedFluoxetine-induced weight loss in overweight non-depressed humans.
116 Citations1987James M. Ferguson, John P. Feighner
Fluoxetine is shown to be a potent anorectic agent in non-depressed clinically overweight individuals and as effective an anorexic compound as a currently available appetite control agent, benzphetamine, and highly significantly more effective than the placebo treatment.
JAMACardiac Valvulopathy Associated With Exposure to Fenfluramine or Dexfenfluramine: US Department of Health and Human Services Interim Public Health Recommendations, November 1997
116 Citations1997
The data used by FDA in its decision to request voluntary withdrawal of these drugs from the market is summarized, and interim public health recommendations for persons exposed to these drugs are presented.
PubMedA one-year trial to assess the value of orlistat in the management of obesity.
116 Citations1997W. P. T. James, Alison Avenell +2 more
This preliminary analysis suggests that orlistat, when used with a health-promoting low-fat and moderately energy-restricted diet, confers advantages in the long-term management of obesity.
International Journal of ObesityFluoxetine improves insulin sensitivity in obese patients with non-insulin-dependent diabetes mellitus independently of weight loss
111 Citations1997Pierre Maheux, F Ducros +3 more
Fluoxetine improves insulin-mediated glucose disposal in obese patients with non-insulin-dependent diabetes mellitus with NIDDM independently of weight loss.
Journal of HypertensionTreatment with orlistat reduces cardiovascular risk in obese patients
109 Citations1998James H. Zavoral
Orlistat was well tolerated and had a similar safety profile to placebo, and orlistat-treated patients had significantly greater improvements in several lipid parameters including total cholesterol, low-density lipoproteincholesterol, triglycerides, and apolipoprotein B.
International Journal of ObesityA clinical trial of the use of Sibutramine for the treatment of patients suffering essential obesity
108 Citations2000Guillermo Fanghänel, Leonides Cortinas +2 more
Sibutramine induces significant loss of body weight, BMI and waist, but does not significantly affect cardiovascular function and was well tolerated by most the patients.
British Journal of PharmacologyA comparison of the effects on central 5‐HT function of sibutramine hydrochloride and other weight‐modifying agents
105 Citations1998D.J. Heal, Sharon C. Cheetham +3 more
Results show that sibutramine powerfully enhances central 5‐HT function via its secondary and primary amine metabolites; this effect, like that of fluoxetine, is almost certainly mediated through 5‐ HT uptake inhibition.
International Journal of ObesityPredictors of weight loss and maintenance during 2 years of treatment by sibutramine in obesity. Results from the European multi-centre STORM trial
103 Citations2001for the STORM study group, DL Hansen +10 more
Only pre-treatment body weight seems to be an important independent predictor of 6 months weight loss and 24 month weight maintenance in this study on diet and Sib.
Diabetes CareEffects of Sibutramine in Obese Female Subjects With Type 2 Diabetes and Poor Blood Glucose Control
102 Citations2001Adnan Gökçel, Hatice Karakose +4 more
Sibutramine is an effective adjunct to oral hypoglycemic therapy in obese women with type 2 diabetes and resulted in significant weight loss and improvement in metabolic parameters in this patient group.
American Journal of Clinical NutritionLong-term weight loss: the effect of pharmacologic agents
98 Citations1994Goldstein Dj, JH Potvin
The benefits of extended treatment appear to outweigh the risks for those patients who are unable to lose sufficient weight without pharmacologic therapy but who maintain adequate weight loss with long-term pharmacologic Therapy.
Diabetic MedicineFluoxetine in the Treatment of Obese Type 2 Diabetic Patients
94 Citations1994Mary O’Kane, Philip Wiles +1 more
Fluoxetine might prove to be a useful adjunct therapy in obese Type 2 diabetic patients where short‐term weight loss and fall in carbohydrate intake and an improvement in glycaemia are indicated.
Obesity ResearchLifestyle Modification in the Pharmacologic Treatment of Obesity: A Pilot Investigation of a Potential Primary Care Approach
92 Citations1997Thomas A. Wadden, Robert I. Berkowitz +4 more
Weight loss the first four weeks, as well as patient completion of daily food records during the first 18 weeks, correlated positively with weight loss at weeks 18, 26, and 52.
American Journal of Clinical NutritionEnhanced thermogenic responsiveness during chronic ephedrine treatment in man
90 Citations1985Arne Astrup, C. Lundsgaard +2 more
The thermogenic effect of a single oral dose of ephedrine (1 mg/kg body weight) was studied by indirect calorimetry in five women with 14% overweight before, during and 2 mo after 3 mo of chronic ephedine treatment to find an improved capacity for beta-adrenergic induced thermogenesis may be useful in the treatment of obesity.
Obesity ResearchEffects of Sibutramine on Resting Metabolic Rate and Weight Loss in Overweight Women
89 Citations1998Helen Seagle, D.H. Bessesen +1 more
While sibutramine was shown to be an effective weight-loss agent over 8 weeks, it was found that it increased RMR, which suggests that the drug does not directly affect RMR.
Diabetes CarePramlintide, a Synthetic Analog of Human Amylin, Improves the Metabolic Profile of Patients With Type 2 Diabetes Using Insulin
87 Citations1998Robert G. Thompson, Leeanne L. Pearson +3 more
Reductions in serum fructosamine, plasma total and LDL cholesterol concentrations, and HbA1c support the hypothesis that pramlintide may improve metabolic control in patients with type 2 diabetes using insulin.
Obesity ResearchAbsence of Cardiac Valve Dysfunction in Obese Patients Treated with Sibutramine
86 Citations1999David S. Bach, Aila Rissanen +8 more
The prevalence of left-sided cardiac valve dysfunction was not higher than background in obese patients treated with sibutramine for an average of 7.6 months.
MetabolismLong-term effects of fluoxetine on glycemic control in obese patients with non-insulin-dependent diabetes mellitus or glucose intolerance: Influence on muscle glycogen synthase and insulin receptor kinase activity
85 Citations1995Leif Breum, Ulla Bjerre +3 more
F seems to improve insulin sensitivity beyond the effect mediated through weight loss by a possible effect on GS activity in skeletal muscle tissue, as well as glycemic regulation improved along with the weight loss.
PubMedEphedrine, caffeine and aspirin: safety and efficacy for treatment of human obesity.
85 Citations1993Paul Daly, Diane Krieger +3 more
ECA in these doses is thus well tolerated in otherwise healthy obese subjects, and supports modest, sustained weight loss even without prescribed caloric restriction, and may be more effective in conjunction with restriction of energy intake.
Archives of Disease in ChildhoodRandomised controlled trials
85 Citations1997Richard Phillips, TM Rothenberg
It is struck by how easy it is to overlook a randomised controlled trial (RCT) in the Archives if this is not indicated in the title or abstract.
European PsychiatryLong-term effects of topiramate on bipolar mood instability, weight change and glycemic control: a case-series
84 Citations2001K. N. Roy Chengappa, Jay F. Levine +3 more
Topiramate is an antiepileptic agent, which is being investigated as a mood-stabilizer, and three obese individuals with DSM-IV bipolar I disorder and type II diabetes mellitus received topiramate treatment in combination with antipsychotics and valproate or carbamazepine improved mood stability.
Diabetes CareOne-Year Outcome of a Combination of Weight Loss Therapies for Subjects With Type 2 Diabetes
77 Citations2003J. Bruce Redmon, Susan K. Raatz +6 more
A combination weight loss program using intermittent low-calorie diets, energy-controlled meal replacement products, and sibutramine resulted in greater weight loss and improved diabetes control compared with a standard weight Loss program in overweight or obese subjects with type 2 diabetes.
…